LoginSignup
Valneva logo

Valneva Stock

StockStock
ISIN: FR0004056851
Ticker: VLA
FR0004056851
VLA

Price

Frequently asked questions

What is Valneva's market capitalization?

The market capitalization of Valneva is $410.73M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Valneva?

Valneva's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.0601. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Valneva's stock?

Currently, 8 analysts cover Valneva's stock, with a consensus target price of $9.917. Analyst ratings provide insights into the stock's expected performance.

What is Valneva's revenue over the trailing twelve months?

Over the trailing twelve months, Valneva reported a revenue of $167.25M.

What is the EBITDA for Valneva?

Valneva's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $46.20M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Valneva?

Valneva has a free cash flow of -$177.93M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Valneva's stock?

The 5-year beta for Valneva is 0.72. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Valneva have, and what sector and industry does it belong to?

Valneva employs approximately 695 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Valneva's shares?

The free float of Valneva is 119.89M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $410.73M

5Y beta

 0.72

EPS (TTM)

 -$0.0601

Free Float

 119.89M

Revenue (TTM)

 $167.25M

EBITDA (TTM)

 $46.20M

Free Cashflow (TTM)

 -$177.93M

Pricing

1D span
$2.367$2.57
52W span
$2.387$6.463

Analyst Ratings

The price target is $9.917 and the stock is covered by 8 analysts.

Buy

7

Hold

1

Sell

0

Information

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

695

Biotechnology & Drugs

Health Care

Identifier

ISIN

FR0004056851

Primary Ticker

VLA

Knockouts

Join the conversation
Sign upLogin